ZA201602839B - Methods of using interleukin-10 for treating diseases and disorders - Google Patents
Methods of using interleukin-10 for treating diseases and disordersInfo
- Publication number
- ZA201602839B ZA201602839B ZA2016/02839A ZA201602839A ZA201602839B ZA 201602839 B ZA201602839 B ZA 201602839B ZA 2016/02839 A ZA2016/02839 A ZA 2016/02839A ZA 201602839 A ZA201602839 A ZA 201602839A ZA 201602839 B ZA201602839 B ZA 201602839B
- Authority
- ZA
- South Africa
- Prior art keywords
- interleukin
- disorders
- methods
- treating diseases
- diseases
- Prior art date
Links
- 102000003814 Interleukin-10 Human genes 0.000 title 1
- 108090000174 Interleukin-10 Proteins 0.000 title 1
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 229940076144 interleukin-10 Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361902702P | 2013-11-11 | 2013-11-11 | |
| PCT/US2014/064620 WO2015070060A1 (en) | 2013-11-11 | 2014-11-07 | Methods of using interleukin-10 for treating diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201602839B true ZA201602839B (en) | 2017-09-27 |
Family
ID=53042151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2016/02839A ZA201602839B (en) | 2013-11-11 | 2016-04-25 | Methods of using interleukin-10 for treating diseases and disorders |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11413332B2 (enExample) |
| EP (1) | EP3068425B1 (enExample) |
| JP (1) | JP6660297B2 (enExample) |
| KR (1) | KR20160079114A (enExample) |
| CN (2) | CN120242030A (enExample) |
| AU (1) | AU2014346537A1 (enExample) |
| BR (1) | BR112016010166A2 (enExample) |
| CA (1) | CA2928710A1 (enExample) |
| ES (1) | ES2862139T3 (enExample) |
| IL (1) | IL245303A0 (enExample) |
| MX (1) | MX2016005915A (enExample) |
| PH (1) | PH12016500840A1 (enExample) |
| RU (1) | RU2016122957A (enExample) |
| WO (1) | WO2015070060A1 (enExample) |
| ZA (1) | ZA201602839B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9943568B2 (en) | 2013-04-18 | 2018-04-17 | Armo Biosciences, Inc. | Methods of using pegylated interleukin-10 for treating cancer |
| US9823255B2 (en) | 2013-06-17 | 2017-11-21 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
| EP3038642A4 (en) | 2013-08-30 | 2017-01-18 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| EP3068425B1 (en) | 2013-11-11 | 2021-01-27 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| ES2770684T3 (es) | 2014-03-14 | 2020-07-02 | Novartis Ag | Moléculas de anticuerpos contra LAG-3 y usos de los mismos |
| CN106573072A (zh) | 2014-06-02 | 2017-04-19 | 阿尔莫生物科技股份有限公司 | 降低血清胆固醇的方法 |
| RU2718914C2 (ru) | 2014-09-13 | 2020-04-15 | Новартис Аг | Сочетанные способы лечения с использованием ингибиторов alk |
| AU2015333827A1 (en) | 2014-10-14 | 2017-04-20 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
| CN107106655A (zh) | 2014-10-22 | 2017-08-29 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素‑10治疗疾病和病症的方法 |
| US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
| HK1248137A1 (zh) | 2015-05-28 | 2018-10-12 | 阿尔莫生物科技股份有限公司 | 用於治疗癌症的聚乙二醇化白细胞介素-10 |
| US20190307849A1 (en) * | 2015-05-29 | 2019-10-10 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| AU2016270710A1 (en) | 2015-06-01 | 2017-12-14 | Maine Medical Center Research Institute | Enhancing the therapeutic activity of an immune checkpoint inhibitor |
| SI3334431T1 (sl) * | 2015-08-11 | 2020-01-31 | Novartis Ag | 5-bromo-2,6-di-(1h-pirazol-l-il)pyrimidin-4-amin za uporabo v zdravljenju raka |
| WO2017035232A1 (en) | 2015-08-25 | 2017-03-02 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| EP3377534B1 (en) * | 2015-11-18 | 2025-06-18 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody |
| CA3004748C (en) | 2015-11-18 | 2021-11-16 | Merck Sharp & Dohme Corp. | Pd1 and/or lag3 binders |
| MX2018007295A (es) | 2016-01-11 | 2019-03-28 | Armo Biosciences Inc | Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos. |
| WO2017143115A2 (en) | 2016-02-18 | 2017-08-24 | Maine Medical Center Research Institute | Enhancing the therapeutic activity of an immune checkpoint inhibitor |
| AU2017228329B2 (en) | 2016-03-01 | 2021-03-11 | Corcept Therapeutics, Inc. | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors |
| JP6874147B2 (ja) * | 2017-02-28 | 2021-05-19 | ジーンメディスン・カンパニー・リミテッド | 腫瘍特異的殺傷アデノウイルスおよび免疫チェックポイント阻害剤を含む抗癌用組成物 |
| EP3606947B1 (en) * | 2017-04-03 | 2022-12-21 | F. Hoffmann-La Roche AG | Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody |
| GB201714430D0 (en) * | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| CN111315398A (zh) * | 2017-11-10 | 2020-06-19 | 阿尔莫生物科技股份有限公司 | 白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法 |
| MX2020010036A (es) | 2018-03-28 | 2021-03-02 | Herbalife Int Of America Inc | Acetilacion de polisacaridos. |
| US20210347842A1 (en) * | 2018-06-19 | 2021-11-11 | Eli Lilly And Company | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy |
| GB201810058D0 (en) * | 2018-06-19 | 2018-08-08 | Cytovation As | Combination therapy using a peptide |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| CN113347990A (zh) * | 2018-12-21 | 2021-09-03 | 西北大学 | 膜联蛋白在预防和治疗肌膜损伤中的用途 |
| CN113811549A (zh) | 2019-02-21 | 2021-12-17 | Xencor股份有限公司 | 非靶向和靶向性il-10 fc融合蛋白 |
| BR102019007044A2 (pt) | 2019-04-05 | 2021-12-28 | Universidade Federal de Uberlândia | Peptídeos sintéticos com afinidade ao receptor de interleucina-10, composição farmacêutica e uso dos mesmos como imunomuduladores no tratamento de doenças autoimunes, inflamatórias ou alérgicas |
| US20220306713A1 (en) * | 2019-06-10 | 2022-09-29 | Apollomics Inc. (Hangzhou) | Antibody-interleukin fusion protein and methods of use |
| MX2022001975A (es) | 2019-08-16 | 2022-03-11 | Applied Molecular Transport Inc | Composiciones, formulaciones y produccion y purificacion de interleucinas. |
| EP4149963A1 (en) | 2020-05-12 | 2023-03-22 | Regeneron Pharmaceuticals, Inc. | Novel il10 agonists and methods of use thereof |
| US20240190934A1 (en) * | 2022-11-28 | 2024-06-13 | Elixiron Immunotherapeutics (hong Kong) Limited | Engineered interleukin-10 and fusion proteins thereof |
Family Cites Families (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1202840A (en) | 1985-06-10 | 1986-04-08 | Jonathan R. Kleinsasser | Combination wet and dry feeder for animals |
| JPS63152393A (ja) | 1986-07-03 | 1988-06-24 | Takeda Chem Ind Ltd | グリコシル誘導体 |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US5714585A (en) | 1987-10-26 | 1998-02-03 | Sterling Winthrop, Inc. | Antibodies that are immunoreactive with interleukin-7 |
| US5032396A (en) | 1989-02-17 | 1991-07-16 | Immunex Corporation | IL-7 to stimulate platelet production |
| US6217857B1 (en) | 1989-06-28 | 2001-04-17 | Schering Corporation | Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof |
| US5231012A (en) | 1989-06-28 | 1993-07-27 | Schering Corporation | Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10) |
| US5229115A (en) | 1990-07-26 | 1993-07-20 | Immunex Corporation | Adoptive immunotherapy with interleukin-7 |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| ATE116550T1 (de) | 1991-01-16 | 1995-01-15 | Schering Corp | Behandlung von neoplastischen krankenheiten mit interleukin-10. |
| JPH06505250A (ja) | 1991-01-16 | 1994-06-16 | シェリング・コーポレーション | 癌の養子免疫療法におけるインターロイキン−１０の使用 |
| US5624823A (en) | 1991-11-22 | 1997-04-29 | The General Hospital Corporation | DNA encoding procine interleukin-10 |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| AU6000894A (en) | 1993-02-01 | 1994-08-29 | Michel Goldman | Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10 |
| US5328989A (en) | 1993-03-05 | 1994-07-12 | Schering-Plough | Purification of human interleukin-10 from a cell culture medium |
| US5552303A (en) | 1993-03-08 | 1996-09-03 | Immunex Corporation | DNA encoding epithelium-derived T-cell factor |
| WO1994022473A1 (en) | 1993-04-01 | 1994-10-13 | University Of Washington | Use of interleukin 7 to improve vaccine potency |
| US5665345A (en) | 1993-05-24 | 1997-09-09 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of inhibiting viral replication using IL-10 |
| CA2168110A1 (en) | 1993-07-26 | 1995-02-02 | Chuan-Chu Chou | Agonists and antagonists of human interleukin-10 |
| GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| AU707019B2 (en) | 1994-01-20 | 1999-07-01 | Schering Corporation | Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity |
| US5696234A (en) | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
| US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6410008B1 (en) | 1994-12-12 | 2002-06-25 | Beth Israel Hospital Association | Chimeric IL-10 proteins and uses thereof |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5866134A (en) | 1995-03-24 | 1999-02-02 | Schering Corporation | Method for enhancing the antibody response to specific antigens with Interleukin-10 |
| US5770190A (en) | 1995-07-14 | 1998-06-23 | Schering Corporation | Method of treatment of acute leukemia with inteleukin-10 |
| GB2304047A (en) | 1995-08-09 | 1997-03-12 | Univ Manchester | Pharmaceutical compositions containing cytokines |
| US5744451A (en) | 1995-09-12 | 1998-04-28 | Warner-Lambert Company | N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US5759859A (en) | 1996-07-15 | 1998-06-02 | United States Of America As Represented By The Secretary Of The Army | Sensor and method for detecting trace underground energetic materials |
| US5945097A (en) | 1996-09-06 | 1999-08-31 | Schering Corporation | Method for lowering cholesterol levels with interleukin-10 |
| US5989867A (en) | 1996-09-23 | 1999-11-23 | Knappe; Andrea | DNA encoding IL-10-like homologue; related reagents |
| US6660258B1 (en) | 1997-05-09 | 2003-12-09 | Pharma Pacific Pty Ltd | Oromucosal cytokine compositions and uses thereof |
| ES2297889T3 (es) | 1997-07-14 | 2008-05-01 | Bolder Biotechnology, Inc. | Derivados de hormona de crecimiento y proteinas relacionadas. |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| PT1053019E (pt) | 1998-01-07 | 2004-04-30 | Debio Rech Pharma Sa | Acrilatos de poli(etileno-glicol) heterobifuncional degradaveis e geles e conjugados derivados dos mesmos |
| US6428985B1 (en) | 1998-12-02 | 2002-08-06 | The Regents Of The University Of Michigan | Immunosuppressive structural definition of IL-10 |
| JP2002532556A (ja) | 1998-12-22 | 2002-10-02 | シェリング・コーポレーション | Ｃ型肝炎ウイルス感染のインターロイキン−１０での処置 |
| US7666400B2 (en) | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
| WO2001005821A2 (en) | 1999-07-16 | 2001-01-25 | Maria Teresa Bejarano | Viral il-10 for the inhibition of angiogenesis, tumorigenesis and metastasis |
| US6989377B2 (en) | 1999-12-21 | 2006-01-24 | Wisconsin Alumni Research Foundation | Treating vitamin D responsive diseases |
| US20030186386A1 (en) | 2000-02-11 | 2003-10-02 | Hansen Christian Karsten | Interleukin 10 |
| EP1257574A1 (en) | 2000-02-11 | 2002-11-20 | Maxygen Aps | Improved interleukin 10 |
| ES2367891T3 (es) | 2000-09-29 | 2011-11-10 | Schering Corporation | Interleucina-10 pegilada. |
| JP2002142770A (ja) | 2000-11-08 | 2002-05-21 | Dnavec Research Inc | 循環系への遺伝子送達用パラミクソウイルスベクター |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| EP1234583A1 (en) | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | PEG-conjugates of HGF-NK4 |
| WO2002085300A2 (en) | 2001-04-23 | 2002-10-31 | The Regents Of The University Of California | Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts |
| GB0212648D0 (en) | 2002-05-31 | 2002-07-10 | Immunoclin Lab Ltd | Treatment with cytokines |
| EP1391513A1 (en) | 2002-08-08 | 2004-02-25 | Cytheris | IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof |
| WO2004022593A2 (en) | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| AU2003280315A1 (en) | 2002-11-14 | 2004-06-03 | Maxygen, Inc. | Conjugates of interleukin-10 and polymers |
| AU2003292137A1 (en) | 2002-11-29 | 2004-06-23 | Maria Grazia Roncarolo | Rapamycin and il-10 for the treatment of immune diseases |
| AU2003303222A1 (en) | 2002-12-19 | 2004-07-14 | Universiteit Gent | Mutant proteins showing increased secretion |
| CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| TWI364295B (en) | 2002-12-26 | 2012-05-21 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| EP1603935A4 (en) | 2003-03-03 | 2007-03-21 | Dyax Corp | SPECIFIC TO HGF RECEPTOR (cMET) BINDING PEPTIDES AND THEIR USE |
| DE602004025799D1 (de) | 2003-04-15 | 2010-04-15 | Glaxosmithkline Llc | Humane il-18 substitutionsmutanten und deren konjugate |
| US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| JPWO2005033307A1 (ja) | 2003-09-30 | 2006-12-14 | 技術研究組合 生物分子工学研究所 | 新規のリフォールディング方法およびその方法によって得られたタンパク質 |
| WO2005052159A1 (en) | 2003-11-28 | 2005-06-09 | The University Of Sydney | Latent phase viral interleukin-10-(vii-10) and uses thereof |
| ES2305886T3 (es) | 2003-12-30 | 2008-11-01 | Merck Patent Gmbh | Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo. |
| US20060078942A1 (en) | 2004-03-10 | 2006-04-13 | Pepgen Corporation | Method of treatment using interferon-tau |
| WO2005092928A1 (en) | 2004-03-11 | 2005-10-06 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
| DK2997980T3 (en) | 2004-08-10 | 2018-03-26 | Kastle Therapeutics Llc | PROCEDURES FOR MODULATING LIPROPROTEIN AND CHOLESTEROL LEVELS |
| US20060046961A1 (en) | 2004-09-02 | 2006-03-02 | Mckay William F | Controlled and directed local delivery of anti-inflammatory compositions |
| CN100334112C (zh) | 2004-10-15 | 2007-08-29 | 上海海欣生物技术有限公司 | 人白细胞介素15与Fc融合蛋白 |
| BRPI0519000A2 (pt) | 2004-12-09 | 2008-12-23 | Merck Patent Gmbh | variantes de il-7 com imunogenicidade reduzida |
| GB0500643D0 (en) | 2005-01-13 | 2005-02-23 | Renovo Ltd | Medicaments |
| WO2006094530A1 (en) | 2005-03-11 | 2006-09-14 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| AR052741A1 (es) | 2005-04-08 | 2007-03-28 | Noxxon Pharma Ag | Acidos nucleicos de union a ghrelin |
| US20100028296A1 (en) | 2005-05-02 | 2010-02-04 | Chavez Raymond A | Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease |
| KR101498834B1 (ko) * | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| EP1891103B1 (en) | 2005-05-31 | 2009-12-23 | The Regents of the University of Colorado | Mutant il-10 |
| EP1910513B1 (en) | 2005-07-01 | 2016-08-10 | John Schrader | Methods of isolating antibody secreting cells from blood samples of immunized animals and generating monoclonal antibodies from said antibody secreting cells. |
| EP1746161A1 (en) | 2005-07-20 | 2007-01-24 | Cytheris | Glycosylated IL-7, preparation and uses |
| JP5364375B2 (ja) | 2005-10-04 | 2013-12-11 | ザイモジェネティクス リミテッド ライアビリティ カンパニー | Ｉｌ−２９の生産および精製の方法 |
| US7939056B2 (en) | 2005-11-14 | 2011-05-10 | The Brigham And Women's Hospital, Inc. | Interleukin-10 compositions for the treatment of adenocarcinomas |
| US7868139B2 (en) | 2006-01-24 | 2011-01-11 | Uab Research Foundation | Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases |
| US7662965B2 (en) * | 2006-01-26 | 2010-02-16 | Cornerstone Therapeutics, Inc. | Anabaseine derivatives, pharmaceutical compositions and method of use thereof |
| BRPI0719446A2 (pt) | 2006-09-28 | 2013-12-10 | Schering Corp | Uso de il-10 peguilada para tratar câncer |
| WO2008041953A2 (en) | 2006-10-05 | 2008-04-10 | Agency For Science, Technology And Research | Dengue diagnosis and treatment |
| CA2708004C (en) | 2006-12-04 | 2015-12-01 | Promedior, Inc. | Conjoint therapy for treating fibrotic diseases |
| AU2008206077A1 (en) | 2007-01-19 | 2008-07-24 | Kai Pharmaceuticals, Inc. | Modifications of peptide compositions to increase stability and delivery efficiency |
| WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| CN104710518A (zh) | 2007-07-31 | 2015-06-17 | 阿菲博迪公司 | 新白蛋白结合组合物、方法及应用 |
| WO2009036568A1 (en) | 2007-09-19 | 2009-03-26 | University Health Network | Methods and compositions for treating tumors and viral infections |
| EP2959917A3 (en) | 2007-10-19 | 2016-02-24 | The Regents of The University of California | Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss |
| EP2219458B1 (en) | 2007-11-08 | 2015-07-15 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
| GB0724231D0 (en) | 2007-12-12 | 2008-01-30 | Renono Ltd | Methods for inhibiting scarring |
| US20090311187A1 (en) | 2008-05-29 | 2009-12-17 | Bristol-Myers Squibb Company | Methods for predicting patient response to modulation of the Co-stimulatory pathway |
| WO2010022227A1 (en) | 2008-08-20 | 2010-02-25 | Schering Corporation | Methods for monitoring il-10 therapy |
| KR20110112301A (ko) | 2008-11-18 | 2011-10-12 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
| ES2655364T3 (es) * | 2008-12-17 | 2018-02-19 | Merck Sharp & Dohme Corp. | Producción de IL-10 mono- y dipegilada y sus usos |
| CA2769822C (en) * | 2009-08-13 | 2019-02-19 | The Johns Hopkins University | Methods of modulating immune function |
| EP2486049A1 (en) | 2009-10-06 | 2012-08-15 | The Board Of Trustees Of The UniversityOf Illinois | Human single-chain t cell receptors |
| EP2488553B1 (en) | 2009-10-12 | 2015-06-17 | Pfizer Inc. | Cancer treatment |
| RU2607374C2 (ru) | 2009-10-30 | 2017-01-10 | Новозаймс Байофарма Дк А/С | Варианты альбумина |
| CA2782007C (en) | 2009-11-30 | 2018-07-24 | Biotest Ag | Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle) |
| EP3798237A1 (en) * | 2010-03-05 | 2021-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| SG186302A1 (en) | 2010-06-16 | 2013-02-28 | Abbott Lab | Comparison of protein samples |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| DK2590993T3 (en) | 2010-07-09 | 2015-06-29 | Affibody Ab | Polypeptides |
| US8759617B2 (en) | 2010-09-21 | 2014-06-24 | National Institute Of Agrobiological Sciences | Method for extraction and purification of recombinant proteins from transgenic plants |
| JP6121330B2 (ja) | 2010-09-28 | 2017-04-26 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 作用持続時間が増した改変ポリペプチド |
| BR122021020041B1 (pt) | 2010-09-28 | 2023-03-07 | Amylin Pharmaceuticals, Llc | Polipeptídeo quimérico, seu uso e composição que o compreende |
| US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
| JP6203705B2 (ja) | 2011-03-23 | 2017-09-27 | フレッド ハッチンソン キャンサー リサーチ センター | 細胞免疫療法のための方法および組成物 |
| CN102145178B (zh) | 2011-04-15 | 2012-09-26 | 北京凯因科技股份有限公司 | Peg化白介素15 |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| US20140242081A1 (en) * | 2011-07-18 | 2014-08-28 | Micromet Ag | Dosing regimens for treatment of cea-expressing cancers |
| US20140256626A1 (en) | 2011-10-18 | 2014-09-11 | Prolynx Llc | Peg conjugates of exenatide |
| US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| CA2862745A1 (en) | 2012-01-26 | 2013-08-01 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) polypeptides |
| HK1205746A1 (en) | 2012-02-29 | 2015-12-24 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates and their uses |
| US20150118244A1 (en) | 2012-05-10 | 2015-04-30 | Bristol-Myers Squibb Company | Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients |
| EP2947111B1 (en) | 2013-01-17 | 2018-03-07 | Xiamen Sinopeg Biotech Co., Ltd. | Monofunctional branched polyethyleneglycol and bio-related substance modified by same |
| US9943568B2 (en) | 2013-04-18 | 2018-04-17 | Armo Biosciences, Inc. | Methods of using pegylated interleukin-10 for treating cancer |
| EP2989240A4 (en) | 2013-04-24 | 2016-10-19 | Armo Biosciences Inc | INTERLEUKIN-10 COMPOSITIONS AND USES THEREOF |
| US9823255B2 (en) | 2013-06-17 | 2017-11-21 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
| EP3038642A4 (en) | 2013-08-30 | 2017-01-18 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| EP3068425B1 (en) | 2013-11-11 | 2021-01-27 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| US20160375101A1 (en) | 2014-01-15 | 2016-12-29 | Armo Biosciences, Inc. | Methods of Using Interleukin-10 for Treating Diseases and Disorders |
| EP4303229A3 (en) | 2014-01-21 | 2024-04-17 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| MA39711A (fr) | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
| CN106573072A (zh) | 2014-06-02 | 2017-04-19 | 阿尔莫生物科技股份有限公司 | 降低血清胆固醇的方法 |
| JP2018510863A (ja) | 2015-03-11 | 2018-04-19 | ネクター セラピューティクス | Ｉｌ−７部分とポリマーとのコンジュゲート |
| HK1248137A1 (zh) | 2015-05-28 | 2018-10-12 | 阿尔莫生物科技股份有限公司 | 用於治疗癌症的聚乙二醇化白细胞介素-10 |
-
2014
- 2014-11-07 EP EP14860137.0A patent/EP3068425B1/en active Active
- 2014-11-07 AU AU2014346537A patent/AU2014346537A1/en not_active Abandoned
- 2014-11-07 CA CA2928710A patent/CA2928710A1/en not_active Abandoned
- 2014-11-07 KR KR1020167015158A patent/KR20160079114A/ko not_active Withdrawn
- 2014-11-07 JP JP2016528896A patent/JP6660297B2/ja active Active
- 2014-11-07 CN CN202510416932.2A patent/CN120242030A/zh active Pending
- 2014-11-07 BR BR112016010166A patent/BR112016010166A2/pt not_active IP Right Cessation
- 2014-11-07 US US15/031,651 patent/US11413332B2/en active Active
- 2014-11-07 MX MX2016005915A patent/MX2016005915A/es unknown
- 2014-11-07 ES ES14860137T patent/ES2862139T3/es active Active
- 2014-11-07 WO PCT/US2014/064620 patent/WO2015070060A1/en not_active Ceased
- 2014-11-07 RU RU2016122957A patent/RU2016122957A/ru unknown
- 2014-11-07 CN CN201480068159.5A patent/CN105848674A/zh active Pending
-
2016
- 2016-04-25 IL IL245303A patent/IL245303A0/en unknown
- 2016-04-25 ZA ZA2016/02839A patent/ZA201602839B/en unknown
- 2016-05-05 PH PH12016500840A patent/PH12016500840A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016005915A (es) | 2016-12-16 |
| BR112016010166A2 (pt) | 2017-12-05 |
| AU2014346537A1 (en) | 2016-05-19 |
| ES2862139T3 (es) | 2021-10-07 |
| JP6660297B2 (ja) | 2020-03-11 |
| WO2015070060A1 (en) | 2015-05-14 |
| PH12016500840A1 (en) | 2016-07-11 |
| US11413332B2 (en) | 2022-08-16 |
| RU2016122957A (ru) | 2017-12-19 |
| KR20160079114A (ko) | 2016-07-05 |
| CN105848674A (zh) | 2016-08-10 |
| US20160243196A1 (en) | 2016-08-25 |
| JP2016537340A (ja) | 2016-12-01 |
| CA2928710A1 (en) | 2015-05-14 |
| EP3068425A1 (en) | 2016-09-21 |
| EP3068425A4 (en) | 2017-05-17 |
| EP3068425B1 (en) | 2021-01-27 |
| IL245303A0 (en) | 2016-06-30 |
| CN120242030A (zh) | 2025-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201602839B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| EP2986306A4 (en) | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING | |
| IL273688A (en) | Evaluation and treatment of bradykinin-mediated disorders | |
| ZA201601024B (en) | Methods and compositions for treating brain diseases | |
| ZA201702214B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| IL241134B (en) | Method and system for treating neuromotor system dysfunction | |
| EP2958936A4 (en) | METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE | |
| IL241191A0 (en) | Local compositions and methods for treating local disorders | |
| IL240987A0 (en) | Methods for treating solid tumors in children | |
| IL239851B (en) | Methods and compositions for treating diseases that act to remove myelin | |
| EP3038642A4 (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| EP2996771A4 (en) | TREATMENT OF HUMILION AND FEAR STROKES | |
| ZA201506705B (en) | Methods of treating dyskinesia and related disorders | |
| IL241096A0 (en) | Treatment methods | |
| EP2964227A4 (en) | TREATMENT AND PROPHYLAXIS OF RENAL DISEASES | |
| SG10201802808SA (en) | Method of treating ocular disorders | |
| PL3079684T3 (pl) | Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna | |
| IL245613B (en) | Peptides for use in the treatment of inflammatory diseases that are not related to pathogenic factors | |
| GB201322778D0 (en) | Method of treatment | |
| ZA201302565B (en) | Methods for treating hyperuricemia and related diseases | |
| GB201314882D0 (en) | Method of treatment |